湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2025-081 湖南方盛制药股份有限公司 关于参加 2025 年湖南辖区上市公司投资者网上集体 接待日暨半年度业绩说明会活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步加强与投资者的互动交流，湖南方盛制药股份有限 公司（以下简称"公司"）将参加由湖南证监局、湖南省上市公 司协会与深圳市全景网络有限公司联合举办的"资本聚三湘 楚 光耀新程——2025 年湖南辖区上市公司投资者网上集体接待日 暨半年度业绩说明会"活动，现将相关事项公告如下： 湖南方盛制药股份有限公司董事会 2025年9月12日 第 1 页，共 1 页 本次活动将采用网络远程的方式举行，投资者可登录"全景 路演"网站（https://rs.p5w.net），或关注微信公众号：全景财经， 或下载全景路演 APP，参与本次互动交流，活动时间为 2025 年 9 月 19 日（星期五）14:0 ...

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2025-080 湖南方盛制药股份有限公司 2025年半年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/9/17 | － | 2025/9/18 | 2025/9/18 | 差异化分红送转：否 一、 通过分配方案的股东会届次和日期 本次利润分配方案经公司2025 年 5 月 20 日的2024年年度股东 大会审议通过，授权董事会办理中期利润分配相关事宜，并经公 司 2025 年 8 月 27 日召开第六届董事会第三次会议审议通过。 二、 分配方案 1.发放年度：2025年半年度 2.分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登 记 ...

Core Insights - The stock price of Fangsheng Pharmaceutical has decreased by 2.01% on September 9, trading at 11.21 CNY per share with a market capitalization of 4.922 billion CNY [1] - The company has experienced a year-to-date stock price increase of 10.33%, but has seen a decline of 2.94% over the last five trading days [1] Financial Performance - For the first half of 2025, Fangsheng Pharmaceutical reported a revenue of 834 million CNY, a year-on-year decrease of 8.35%, while the net profit attributable to shareholders increased by 23.67% to 169 million CNY [2] - Cumulative cash dividends since the company's A-share listing amount to 623 million CNY, with 418 million CNY distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders has increased to 33,100, with an average of 13,245 circulating shares per shareholder, a slight decrease of 0.36% [2] - The top three circulating shareholders include ICBC Medical Health Stock, holding 5.3997 million shares, and Rongtong Health Industry Flexible Allocation Mixed Fund, which increased its holdings by 500,000 shares to 5 million [3]

Core Viewpoint - Fangsheng Pharmaceutical announced that its subsidiary, Guangdong Fangsheng Runkang Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for a clinical trial of a gynecological hemostatic and analgesic granule project, marking a significant step in its drug innovation efforts [1] Group 1 - The clinical trial approval was granted on September 3, 2025, indicating the company's progress in drug development [1] - The project focuses on gynecological applications, which may address specific medical needs in this area [1]

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2025-079 湖南方盛制药股份有限公司 关于控股子公司中药创新药研发项目获得药物临床 试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 9 月 3 日，湖南方盛制药股份有限公司（以下简称 "公司"或"方盛制药"）控股子公司广东方盛融科药业有限公 司（以下简称"方盛融科"）中药创新药研发项目妇科止血消痛 颗粒收到国家药品监督管理局核准签发的《药物临床试验批准通 知书》。现将相关情况公告如下： 一、药物的基本情况 药物名称：妇科止血消痛颗粒 剂型：颗粒剂 注册分类：中药 1.1 类 申请事项：临床试验 受理号：CXZL2500039 审批结论：根据《中华人民共和国药品管理法》及有关规定， 经审查，2025 年 6 月 12 日受理的妇科止血消痛颗粒符合药品注 册的有关要求，在进一步完善临床试验方案的基础上，同意本品 开展 II、III ...

Core Viewpoint - Fangsheng Pharmaceutical (603998) announced that its subsidiary, Guangdong Fangsheng Runkang Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for a clinical trial of a traditional Chinese medicine product aimed at treating postpartum hemorrhage and pain [1]. Group 1 - The approved product is a traditional Chinese medicine formulation for the treatment of postpartum conditions characterized by prolonged lochia, abdominal pain, and other symptoms [1]. - The specific symptoms addressed by the product include excessive lochia, abdominal pain upon touch, dark purple blood clots, fatigue, and lower abdominal distension [1]. - The approval signifies a potential advancement in the company's product pipeline and may enhance its market position in the traditional Chinese medicine sector [1].

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) announced that its subsidiary, Guangdong Fangsheng R&D Pharmaceutical Co., Ltd. (referred to as "Fangsheng R&D"), has received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration for its innovative traditional Chinese medicine project, the Gynecological Hemostasis and Pain Relief Granules [1] Group 1 - The National Medical Products Administration has approved the clinical trial for the product, allowing the company to proceed with Phase II and III clinical trials after further refining the clinical trial protocol [1]

Group 1 - The core point of the article is that Fangsheng Pharmaceutical's subsidiary, GuangDong Fangsheng R&D Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for its innovative traditional Chinese medicine project, specifically the gynecological hemostatic and analgesic granules [1] - The approval allows the company to conduct Phase II and III clinical trials after further refining the clinical trial protocol [1]

Core Insights - The report from Huayuan Securities indicates that Fangsheng Pharmaceutical achieved a net profit attributable to shareholders of 169 million yuan in the first half of the year, representing a year-on-year growth of 23.67% [1] - In the second quarter, the net profit attributable to shareholders was 81 million yuan, with a year-on-year increase of 21.50% [1] - The performance in the first half of 2025 met expectations, with a continued focus on the pharmaceutical manufacturing core business [1] Financial Performance - The net profit for the first half of 2025 was 169 million yuan, showing a growth of 23.67% compared to the previous year [1] - The second quarter's net profit was 81 million yuan, reflecting a year-on-year growth of 21.50% [1] Business Focus - The company continues to concentrate on its core pharmaceutical manufacturing operations [1]

Core Viewpoint - The company reported its mid-year results for 2025, showing a decline in revenue but an increase in net profit, indicating a strong performance in specific segments despite overall challenges [1][2]. Group 1: Financial Performance - In the first half of 2025, the company achieved operating revenue of 834 million yuan, a year-on-year decrease of 8.35% [1]. - The net profit attributable to shareholders reached 169 million yuan, reflecting a year-on-year increase of 23.67% [1]. - The net profit excluding non-recurring items was 141 million yuan, up 27.79% year-on-year [1]. Group 2: Business Segments - The pharmaceutical industrial segment generated 768 million yuan in revenue, down 8.20% year-on-year [1]. - Cardiovascular drugs saw revenue of 276 million yuan, marking a growth of 16.05% year-on-year, with strong sales of key products [1]. - The company successfully expanded its market for traditional Chinese medicine (TCM) innovative drugs, with significant progress in products like pediatric cough granules and bone health tablets [1]. Group 3: Future Outlook - The company has established a product cluster primarily focused on TCM innovative drugs, supplemented by chemical drugs and early-stage innovative drugs [2]. - Revenue growth projections for 2025-2027 are estimated at 3.3%, 11.5%, and 11.7%, respectively, while net profit growth is expected at 20.2%, 20.3%, and 20.0% [2]. - The investment rating is maintained at "Buy-A" with a target price of 13.97 yuan over the next six months [2].